| Phase 3 |
| NCT06127407 |
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional… |
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen |
Recruiting |
| NCT05907057 |
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult… |
Acute Myeloid Leukemia (AML) |
Recruiting |
| NCT06465953 |
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… |
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) |
Recruiting |
| NCT05615818 |
Personalized Medicine for Advanced Biliary Cancer Patients |
Biliary Tract Neoplasms |
Recruiting |
| Phase 2 |
| NCT07392242 |
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by… |
Acute Myeloid Leukemia |
Recruiting |
| NCT06707493 |
Ivosidenib as Post-HSCT Maintenance for AML |
IDH1 Mutation |
Recruiting |
| NCT04493164 |
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or… |
Acute Myeloid Leukemia With Gene Mutations |
Recruiting |
| NCT07607418 |
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS |
AML (Acute Myeloid Leukemia) |
Recruiting |
| NCT07548710 |
Study of SA+X in the Treatment of Newly Diagnosed AML |
Acute Myeloid Leukemia |
Recruiting |
| NCT07260175 |
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in… |
Cholangiocarcinoma |
Recruiting |
| NCT05401097 |
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of… |
Acute Myeloid Leukemia |
Recruiting |
| NCT04278781 |
AG-120 in People With IDH1 Mutant Chondrosarcoma |
Chondrosarcoma |
Active, Not Recruiting |
| NCT04195555 |
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic… |
Recurrent Ependymoma |
Active, Not Recruiting |
| NCT03155620 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed… |
Advanced Malignant Solid Neoplasm |
Active, Not Recruiting |
| Phase 1/2 |
| NCT03471260 |
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1… |
Acute Myeloid Leukemia |
Recruiting |
| NCT06501625 |
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in… |
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation |
Recruiting |
| NCT04774393 |
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for… |
Acute Myeloid Leukemia |
Recruiting |
| NCT02677922 |
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase… |
Leukemia, Myeloid, Acute |
Active, Not Recruiting |
| Phase 1 |
| NCT05010772 |
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or… |
Acute Myeloid Leukemia |
Recruiting |
| NCT05756777 |
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute… |
Acute Myeloid Leukemia (AML) |
Recruiting |
| NCT02632708 |
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy… |
Newly Diagnosed Acute Myeloid Leukemia (AML) |
Active, Not Recruiting |